Effectiveness of Esketamine Nasal Spray in Treating Treatment-Resistant Depression: Breakthrough Results and Lower Relapse Rate
2023-10-27 07:04:31 Up to 30 percent of people with severe depression respond poorly to serotonin or serotonin-norepinephrine reuptake inhibitors (SSRI/SNRI). The active ingredient quetiapine is then usually added to them. This standard treatment achieved worse results compared to SSRI/SNRI plus esketamine nasal spray: With the esketamine nasal spray, 54 percent more sufferers achieved a reduction … Read more